α-Thujone

CAT:
804-HY-121618-01
Size:
50 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
α-Thujone - image 1

α-Thujone

  • UNSPSC Description:

    α-Thujone is a monoterpene isolated from Thuja occidentalis essential oil with potent anti-tumor activities. α-Thujone is a reversible modulator of the GABA type A receptor and the IC50 for α-Thujone is 21 μM in suppressing the GABA-induced currents. α-Thujone induces ROS accumulation-dependent cytotoxicity, also induces cell apoptosis and autophagy. α-Thujone has antinociceptive, insecticidal, and anthelmintic activity, and easily penetrates the blood-brain barrier[1][2][3].
  • Target Antigen:

    Apoptosis; Autophagy; GABA Receptor; Parasite; Reactive Oxygen Species
  • Type:

    Natural Products
  • Related Pathways:

    Anti-infection;Apoptosis;Autophagy;Immunology/Inflammation;Membrane Transporter/Ion Channel;Metabolic Enzyme/Protease;Neuronal Signaling;NF-κB
  • Field of Research:

    Cancer; Infection; Neurological Disease
  • Assay Protocol:

    https://www.medchemexpress.com/α-thujone.html
  • Purity:

    98.07
  • Solubility:

    DMSO : 100 mg/mL (ultrasonic)
  • Smiles:

    O=C1C[C@]2(C(C)C)C[C@]2([H])[C@H]1C
  • Molecular Weight:

    152.237
  • References & Citations:

    [1]Agus HH, et al. Involvement of Pca1 in ROS-mediated apoptotic cell death induced by alpha-thujone in the fission yeast (Schizosaccharomyces pombe). FEMS Yeast Res. 2020 Apr 29. pii: foaa022.|[2]Pudełek M, et al. Therapeutic potential of monoterpene α-thujone, the main compound of Thuja occidentalis L. essential oil, against malignant glioblastoma multiforme cells in vitro. Fitoterapia. 2019 Apr;134:172-181.|[3]Höld KM, et al. Alpha-thujone (the active component of absinthe): gamma-aminobutyric acid type A receptor modulation and metabolic detoxification. Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):3826-31.
  • Shipping Conditions:

    Room Temperature
  • Storage Conditions:

    -20°C, 3 years; 4°C, 2 years (Powder)
  • Clinical Information:

    No Development Reported
  • CAS Number:

    546-80-5